Psychiatry Consortium brings Charles River Laboratories and Evotec on board

Medicines Discovery Catapult

World-leading drug discovery organisations Charles River Laboratories and Evotec join the Psychiatry Consortium as drug discovery and development partners.

The two organisations bring invaluable expertise and capabilities to the Psychiatry Consortium, significantly enhancing the offering to the research community.

The Psychiatry Consortium, managed by Medicines Discovery Catapult, brings together academia, industry, charity and government-funded organisations to develop and deliver a portfolio of innovative collaborative projects to identify and validate new targets for psychiatric diseases.

The Psychiatry Consortium, which recently closed its first global call for academic proposals, aims to provide approximately £3 million in research funding over 3 years.

Charles River and Evotec will work closely and collaboratively with the Psychiatry Consortium members, as well as the funded academic researchers to develop and deliver the projects, by providing access to complementary expertise and capabilities.

Through a strong partnership with both organisations, the Psychiatry Consortium will enable the cross-sector exchange of skills and knowledge required to collaboratively advance innovative and impactful drug-discovery projects in psychiatric diseases.

For more information on the Psychiatry Consortium, including details of all members, please visit the Psychiatry Consortium website.